Tessera Defense and Homeland Security Inc. (HLSQ) files reports with the U.S. Securities and Exchange Commission as a NYSE American-listed issuer. These SEC filings document both the company’s current activities as a physical security technology platform and its earlier history as BiomX Inc., a biotechnology business that reported under the PHGE ticker. The registrant’s CIK remains 0001739174 throughout this transition.
Annual reports on Form 10-K and quarterly reports on Form 10-Q provide detail on Tessera’s business description, risk factors, and financial statements. Each report should be read in the context of its reporting period and the business described at that time. Readers should note which periods describe BiomX’s biotechnology operations and which describe Tessera’s security-technology focus.
Current reports on Form 8-K are especially important for understanding key corporate events. An 8-K filed in connection with the September 11, 2026 name and ticker change explains that BiomX Inc. changed its legal name to Tessera Defense and Homeland Security Inc. and that its NYSE American listing transitioned from PHGE to HLSQ. That filing clarifies that the change did not create a new registrant but rebranded the existing company and reflects its shift toward physical security technology.
Other SEC filings, such as registration statements or proxy materials, can provide additional information on capital structure, corporate actions and governance. Historical filings under the BiomX name and PHGE ticker remain part of Tessera’s regulatory record and may be relevant for long-term financial analysis, and subsequent HLSQ filings can be read alongside this retained history to follow the security business.
BiomX Inc. filed an amended current report to add detailed financial information for its recent acquisitions of Israeli defense-technology businesses Zorronet Ltd. and Dr. Frucht Systems Ltd. (DFSL). The filing now includes audited 2025 and 2024 financial statements and Q1 2026 interim results for both companies, plus unaudited pro forma combined figures for BiomX as of year-end 2025 and March 31, 2026. Zorronet reported 2025 revenue of $617 thousand and a net loss of $306 thousand, while DFSL reported 2025 revenue of $292 thousand and a net loss of $119 thousand. Both auditors highlighted substantial doubt about each company’s ability to continue as a going concern, and the notes describe significant geopolitical and security risks tied to operating in Israel.
BiomX Inc. is asking stockholders to vote at its June 26, 2026 virtual annual meeting on three items: electing Class III director Ran Shaked to a term ending at the 2029 annual meeting, approving a major amendment to its 2026 Equity Incentive Plan, and a possible adjournment.
The equity plan amendment would increase the shares of common stock reserved for awards under the 2026 Plan to 6,850,000 shares, up from 1,390,000, while shares outstanding were 11,160,153 as of June 2, 2026. The plan includes an automatic annual “Evergreen Mechanism” adding up to 4% of shares outstanding each year from 2027 through 2036, and features such as double‑trigger change‑in‑control vesting, no repricing without stockholder approval, and clawback provisions.
The proxy also details current board and committee composition, executive and director compensation for 2024–2025, equity award practices, and significant related‑party transactions, including a $3 million Series Y preferred financing with Pyu Pyu Capital LLC and stock‑ and note‑funded acquisitions of Zorro Net Ltd. and Dr. Frucht Systems Ltd. The board unanimously recommends voting “FOR” all three proposals.
BiomX Inc. issued 1,013,637 restricted shares of common stock upon partial conversion of a convertible promissory note originally issued to Mandragola Ltd., turning about $379,000 of principal into equity. These shares were issued as unregistered securities under Section 4(a)(2) of the Securities Act.
The company previously entered into a revolving line of credit of up to $2,000,000 with Mandragola, with each advance evidenced by a 12% convertible promissory note. As additional consideration, BiomX granted Mandragola a five-year warrant to purchase up to 2,000,000 common shares at $12.00 per share, with a cashless exercise feature and subject to stockholder approval. Following this issuance, BiomX has 11,160,153 common shares outstanding.
Deerfield-affiliated funds and James E. Flynn have updated their ownership disclosure in BiomX Inc. through Amendment No. 6 to Schedule 13D. The filing reflects recent warrant exercises and preferred stock conversions into common stock.
On May 27, 2026, each Deerfield fund exercised its Amended and Restated Warrant in full for 66,242 shares of common stock, paying an aggregate exercise price of $125.86 in cash using cash on hand. On May 28, 2026, each fund converted 47,957 shares of Series X Preferred Stock into 252,397 shares of common stock.
After these transactions, Deerfield Management Company, L.P. and Flynn each report beneficial ownership of 889,928 shares of BiomX common stock, representing 8.09% of the 10,783,794 shares of common stock outstanding, while each fund reports 444,703 shares, or 4.08%. Certain warrants remain subject to a 9.99% Beneficial Ownership Limitation, which caps additional exercises that would push their stake above that level.
BiomX Inc. has appointed Roy Rousso as Chief Business Officer, effective July 1, 2026, under a consulting arrangement rather than standard employment. He brings over two decades of leadership experience in digital infrastructure, sovereign cloud, private cellular networks, and technology companies.
Under the consulting agreement dated May 20, 2026, Rousso will receive a pro-rated monthly fee of $11,900 for a 70% engagement, an annual performance bonus opportunity of up to 50% of fees paid, and a proposed equity award of 200,000 shares vesting over three years, with accelerated vesting features upon certain terminations or a change of control.
BiomX Inc. reported Q1 2026 results reflecting a deep strategic shift and severe financial strain. The company is transitioning from biopharma to defense, security and critical‑infrastructure technologies through new subsidiaries DFSL, Zorronet and X Security, whose results are not yet in these statements.
For the quarter, BiomX posted a net loss of $19.1 million and an operating loss of $1.3 million, compared with a $7.8 million operating loss a year earlier. Large non‑cash charges tied to January 2026 Series Y preferred stock and warrant financing, including a $5.2 million day‑one loss and $14.1 million loss from fair‑value changes in derivatives, drove the result.
Cash and cash equivalents were $1.2 million as of March 31, 2026, versus $5.0 million at year‑end 2025, with total assets of $3.3 million and an accumulated deficit of $236.0 million. Management states there is “substantial doubt” about the company’s ability to continue as a going concern and expects existing funds plus anticipated subsidiary revenues will cover operations only for the next several months.
Subsequent to quarter‑end, BiomX acquired 100% of Zorronet and 60% of DFSL and secured a related credit line with Mandragola. The company also received a NYSE American notice for failing stockholders’ equity listing standards and has submitted a remediation plan, with potential delisting if compliance is not restored.
BiomX Inc. amendment to a joint Schedule 13G/A discloses that Rodney Hodges and affiliated entities each report beneficial ownership of 82,618 shares of Common Stock, representing 5.2% of the class. The filing states 1,593,703 shares outstanding as of February 16, 2026.
The filing also notes 33,934 warrants held by Telmina Limited that are exercisable within 60 days of May 14, 2026. The reporting structure is through a chain of holding companies and a Joint Filing Agreement; Mr. Hodges disclaims day-to-day voting or investment control over the reported shares.
BiomX Inc. has fundamentally reshaped its business, exiting phage therapy and pivoting into defense, security, and critical infrastructure technologies. Its former Israeli biotech subsidiary entered insolvency, all clinical programs have stopped, and Adaptive Phage Therapeutics is being wound down after a one-time $800,000 lease settlement.
The company now operates as a holding company over three Israeli-focused defense tech units: 60%-owned LADAR detection specialist DFSL, wholly owned AI security platform Zorronet, and X Security & Defense, which will receive over $3 million of 2026 internal funding. Management and the board were fully replaced and an advisory board was formed, including a former Deputy Head of the Mossad.
The filing highlights heavy dependence on government and prime defense contractors, exposure to Israeli conflict risks, NYSE American non-compliance with a deadline of September 25, 2027, extensive export-control and IIA restrictions, potential dilution from warrants and a $3,000,000 convertible note, and a sizable Zorronet earnout tied to 2026 performance.
BiomX Inc. filed an amended annual report to add Part III information on directors, executive compensation, ownership, related-party transactions and auditor fees, and to update the cover page and officer certifications. No new financial statements are included.
The filing describes a reconstituted board and new leadership team, including CEO Michael Oster and CFO David Rokach, with three independent directors and standard audit, compensation, and nominating committees. It details 2024–2025 pay and outstanding equity awards for former executives who resigned in early 2026 and outlines non-employee director retainers and option grants.
The company discloses several related-party deals: a $3.0 million December 2025 private placement of Series Y Convertible Preferred Stock and warrants with Pyu Pyu Capital, a stock-and-note acquisition of Zorro Net Ltd. from Water IO Ltd., and a largely equity-based acquisition of DR. Frucht Systems Ltd. from Mandragola Ltd. It also notes stockholder approval of a 2026 Equity Incentive Plan for up to 1,390,000 shares, plus an annual evergreen increase.